Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06792890 · ClinicalTrials.gov registry record · NA

A Randomized Controlled Trial of Ambient Artificial Intelligence Scribe Technologies

A NA study of Artificial Intelligence (AI) and Physician Workflow, sponsored by University of California, Los Angeles.

Active
Registry status
NA
Development phase
238
Enrollment target
1
Study location

NCT06792890: Active NA study of Artificial Intelligence (AI) and Physician Workflow, sponsored by University of California, Los Angeles.

NCT06792890 is a NA study of Artificial Intelligence (AI) and Physician Workflow that is active but no longer recruiting, run by University of California, Los Angeles. The registered enrollment target is 238 participants, below the 133,423-participant average among 3 other Artificial Intelligence (AI) trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06792890, a NA study of Artificial Intelligence (AI) and Physician Workflow, is active but no longer recruiting, sponsored by University of California, Los Angeles.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
238 participants
Enrollment target
1
Study location

Study Summary

This is a three-arm pragmatic RCT of 238 outpatient physicians at a large academic health system, randomized 1:1:1 to one of two AI scribe tools or a usual-care control group. The two-month study will observe and compare the effects of each tool prior to system-wide roll out of selected tool (anticipated Spring 2025). We will use covariate-constrained randomization to balance the arms in terms of physician baseline time in notes, survey-measured level of burnout, and clinic days per week. The primary purpose of the initiative is to improve quality, efficiency, and business operations at University of California, Los Angeles (UCLA) Health, and this initiative is not being done for research purposes. The results of this operational initiative will inform the widespread roll out of AI scribe tools across all providers within the UCLA Health System. Nevertheless, the UCLA study team plans to rigorously examine and publish the impact of this intervention across the health system, which is why the study team pre-registered the initiative.

Primary Outcome

The primary outcome measure is the change in provider mean time in notes per note in the second month of the trial from the providers baseline mean time in notes per note for the six months prior to enrollment. This change will be computed on the natural log scale. No patient level information will be collected for this outcome measure.

Interventions

  • OTHER Use Nabla AI Scribe tool provided
  • OTHER Use AI Scribe tool provided by Vendor B

Study Locations (1)

California

  • UCLA Health System - Los Angeles

Trial Details

FieldValue
Enrollment Target 238 participants
Start Date 2024-11-04
Est. Completion 2025-02-28
Phase NA

What the registry record for NCT06792890 still lists

NCT06792890 is an interventional study that assigns participants to a tested intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap, below the 133,423-participant average among 3 other Artificial Intelligence (AI) trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Artificial Intelligence (AI) appearing as the primary indexed condition, and to 2 interventions - of which Use Nabla AI Scribe tool provided is the first listed.

NCT06792890 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06792890 about?

NCT06792890 is a clinical study titled "A Randomized Controlled Trial of Ambient Artificial Intelligence Scribe Technologies". This is a three-arm pragmatic RCT of 238 outpatient physicians at a large academic health system, randomized 1:1:1 to one of two AI scribe tools or a usual-care control group. The two-month study will observe and compare the effects of each tool prior to system-wide roll out of selected tool (antici...

What is the current status of trial NCT06792890?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 238 participants. The study started on 2024-11-04. Estimated completion is 2025-02-28.

What conditions does trial NCT06792890 study?

This clinical trial studies the following conditions: Artificial Intelligence (AI), Physician Workflow.

What interventions are being tested in trial NCT06792890?

The interventions under investigation include: Use Nabla AI Scribe tool provided (OTHER), Use AI Scribe tool provided by Vendor B (OTHER).

Who is sponsoring clinical trial NCT06792890?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06792890 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Artificial Intelligence (AI)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05012072 · 238 participants · NA

    Reducing Pregnancy Risks: The Mastery Lifestyle Intervention

  • NCT05400252 · 238 participants · NA

    Whole Health in VA Mental Health: Omnis Salutis

  • NCT06380517 · 238 participants · Phase 3

    Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age

  • NCT06452797 · 238 participants · NA

    Prognostic Estimates Among ICU Clinicians

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06792890, the US trial registry maintained by the National Library of Medicine. NCT06792890 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.